Curanex Pharmaceuticals Inc
CURX
Company Profile
Business description
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
Contact
2 Jericho Plaza
B Wing, Suite 101
JerichoNY11753
USAT: +1 718 673-6078
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
stocks
Coca-Cola earnings: Billion-dollar brands and consumer engagement remain growth priorities
Despite macro and geopolitical challenges, Coca-Cola managed to increase sales in line with its long-term target.
stocks
Unwarranted drop in ASX share
Jittery investors misinterpret an audit for an existential crisis.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,340.07 | 12.19 | 0.15% |
| DAX 40 | 24,941.73 | 46.12 | -0.18% |
| Dow JONES (US) | 50,252.28 | 64.14 | 0.13% |
| FTSE 100 | 10,445.34 | 91.50 | 0.88% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,107.35 | 4.88 | 0.02% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,507.28 | 60.91 | 0.45% |
| S&P 500 | 6,955.10 | 13.29 | 0.19% |
| S&P/ASX 200 | 9,014.80 | 98.80 | 1.11% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |